Lista de obras - Sandra Tuyaerts - Dominio Público Uruguay

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer

artículo científico publicado en 2018

Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model.

artículo científico publicado en 2018

Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer

artículo científico publicado en 2020

Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity

artículo científico publicado en 2019

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination

scientific article published on 01 January 2008

Dendritic cell immunotherapy in uterine cancer. ⬇️

artículo científico publicado en 2014

Dendritic cell therapy for oncology roundtable conference.

artículo científico publicado en 2011

Dendritic cells differentiated in the presence of IFN-β and IL-3 are potent inducers of an antigen-specific CD8+ T cell response

artículo científico publicado en 2005

Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide

artículo científico publicado en 2003

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

scholarly article by Sandra Tuyaerts & Frédéric Amant published 25 August 2018 in Vaccines

Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA

artículo científico publicado en 2008

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens

scientific article published on 16 January 2012

Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells

artículo científico publicado en 2007

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

artículo científico publicado en 2002

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

artículo científico publicado en 2013

In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.

artículo científico publicado en 2016

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.

artículo científico publicado en 2015

Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.

artículo científico publicado en 2006

Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

artículo científico publicado en 2020

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

artículo científico publicado en 2014

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers

artículo científico publicado en 2006

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

artículo científico publicado en 2004

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

artículo científico publicado en 2019

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

artículo científico publicado en 2018

Potential Therapeutic Targets in Uterine Sarcomas.

artículo científico publicado en 2015

Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform

scientific article published on 08 August 2020

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

artículo científico publicado en 2004

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

artículo científico publicado en 2009

The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer

artículo científico publicado en 2020

The immune system in the normal endometrium and implications for endometrial cancer development.

artículo científico publicado en 2015

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

artículo científico publicado en 2011

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations

artículo científico publicado en 2014

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial

artículo científico publicado en 2013

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

artículo científico publicado en 2016

Lista de obras de Sandra Tuyaerts

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer

Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model.

Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer

Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination

Dendritic cell immunotherapy in uterine cancer. ⬇️

Dendritic cell therapy for oncology roundtable conference.

Dendritic cells differentiated in the presence of IFN-β and IL-3 are potent inducers of an antigen-specific CD8+ T cell response

Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA

Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens

Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.

In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer.

Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.

Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers

Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Potential Therapeutic Targets in Uterine Sarcomas.

Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer

The immune system in the normal endometrium and implications for endometrial cancer development.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).